FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754031560> ?p ?o ?g. }

• W2754031560 abstract "Background To date, rheumatologists do not have curative treatments for connective tissue disease-associated interstitial lung disease (CTD-ILD) (1), therefore an stabilization of the disease is considered as a therapeutic success. One of the most frequent drugs used for achieving this goal is Cyclophosphamide (CYC); however, in the last years there has been an increasing interest in the use of Rituximab (RTX) as a treatment for CTD-ILD. Objectives To compare long-term effectiveness of CYC vs. RTX as a treatment in patients with CTD-ILD. Methods Unicentre and retrospective study in which it was analyzed clinical and image data of 26 CTD-ILD patients treated with CYC or RTX between June 2004 and December 2016. Previously, we checked that baseline characteristics and baseline levels of Pulmonary Function Tests (PFTs) in both groups were similar by using Fisher and T-student tests. The primary outcome of the study was the stabilization of PFTs or HRTC (High Resolution Tomography Computed Tomography) considering as relapse: a) a deterioration ≥10% in FVC (Forced Vital Capacity), or b) a decrement ≥15% in DLCO (diffusing capacity of carbon monoxide), or c) a worsening in HRCT. The prognostic effect of each treatment on stabilization was evaluated using the Kaplan-Meier method and Long Rank test. Subsequently, values of FEV1 (forced expiratory volume in one second), FVC, DLCO and DLCO/VA were compared 12 months after the beginning of the treatment with their corresponding baseline levels in both groups, using paired T-test. Finally, direct comparison between the CYC and the RTX groups was performed at the 12-months time point using T-test. Results The study includes 20 women and 6 men with an average age of 58.9±14.2 years. 14 patients had a diagnosis of Systemic Sclerosis whereas 12 had other types of CTD. From the 26 patients, 15 received CYC and 11 RTX, according to the physician9s decision. Both groups presented similar baseline characteristics and levels in PFTs. The Kaplan-Meier method showed that the treatment had an influence on the stabilization of CTD-ILD, although long Rank test was non-significative. The average of months without relapse in CYC and RTX group was 59.79±9.50 and 79.27±7.81 respectively. Patients in the CYC group did not present any changes in FEV1, FVC, DLCO and DLCO/VA levels during the first year of treatment. In contrast, patients in RTX group showed an increase of all PFTs levels during the first year of monitoring, although these differences were non-significatives. A direct comparison between both treatment groups after 12 months showed lower levels of all PFTs in CYC vs RTX, been DLCO/VA (67.30±10.69 and 86.25±4.59, respectively) statistically significative. Conclusions This study suggests, in patients with ILD-CTD, that CYC treatment stabilizes the lung function, whereas RTX shows a tendency to improve it. Also, patients with RTX treatment shows a larger mean time of stabilization than CYC group. However, large scale randomized controlled trials are needed to confirm these results. References Fischer A, du Bois A. Interstitial lung disease in connective tissue disorders. Lancet 2012;380:689–98. Disclosure of Interest None declared" @default.
• W2754031560 created "2017-09-25" @default.
• W2754031560 creator A5000239274 @default.
• W2754031560 creator A5007097413 @default.
• W2754031560 creator A5013098825 @default.
• W2754031560 creator A5024239387 @default.
• W2754031560 creator A5027515435 @default.
• W2754031560 creator A5027849519 @default.
• W2754031560 creator A5031804690 @default.
• W2754031560 creator A5049123006 @default.
• W2754031560 creator A5050649826 @default.
• W2754031560 creator A5052676135 @default.
• W2754031560 creator A5085763623 @default.
• W2754031560 date "2017-06-01" @default.
• W2754031560 modified "2023-10-15" @default.
• W2754031560 title "AB0619 Connective tissue disease-associated interstitial lung disease treated with cyclophosphamide or rituximab: a unicentre, open-label and comparative study" @default.
• W2754031560 doi "https://doi.org/10.1136/annrheumdis-2017-eular.2072" @default.
• W2754031560 hasPublicationYear "2017" @default.
• W2754031560 type Work @default.
• W2754031560 sameAs 2754031560 @default.
• W2754031560 citedByCount "0" @default.
• W2754031560 crossrefType "proceedings-article" @default.
• W2754031560 hasAuthorship W2754031560A5000239274 @default.
• W2754031560 hasAuthorship W2754031560A5007097413 @default.
• W2754031560 hasAuthorship W2754031560A5013098825 @default.
• W2754031560 hasAuthorship W2754031560A5024239387 @default.
• W2754031560 hasAuthorship W2754031560A5027515435 @default.
• W2754031560 hasAuthorship W2754031560A5027849519 @default.
• W2754031560 hasAuthorship W2754031560A5031804690 @default.
• W2754031560 hasAuthorship W2754031560A5049123006 @default.
• W2754031560 hasAuthorship W2754031560A5050649826 @default.
• W2754031560 hasAuthorship W2754031560A5052676135 @default.
• W2754031560 hasAuthorship W2754031560A5085763623 @default.
• W2754031560 hasBestOaLocation W27540315601 @default.
• W2754031560 hasConcept C126322002 @default.
• W2754031560 hasConcept C141071460 @default.
• W2754031560 hasConcept C16020263 @default.
• W2754031560 hasConcept C165637977 @default.
• W2754031560 hasConcept C2776042228 @default.
• W2754031560 hasConcept C2776670291 @default.
• W2754031560 hasConcept C2776694085 @default.
• W2754031560 hasConcept C2776755627 @default.
• W2754031560 hasConcept C2777524225 @default.
• W2754031560 hasConcept C2777543607 @default.
• W2754031560 hasConcept C2777714996 @default.
• W2754031560 hasConcept C2779075594 @default.
• W2754031560 hasConcept C2779134260 @default.
• W2754031560 hasConcept C2779338263 @default.
• W2754031560 hasConcept C2780333948 @default.
• W2754031560 hasConcept C2780653079 @default.
• W2754031560 hasConcept C3018587741 @default.
• W2754031560 hasConcept C55520419 @default.
• W2754031560 hasConcept C71924100 @default.
• W2754031560 hasConcept C75603125 @default.
• W2754031560 hasConcept C90924648 @default.
• W2754031560 hasConceptScore W2754031560C126322002 @default.
• W2754031560 hasConceptScore W2754031560C141071460 @default.
• W2754031560 hasConceptScore W2754031560C16020263 @default.
• W2754031560 hasConceptScore W2754031560C165637977 @default.
• W2754031560 hasConceptScore W2754031560C2776042228 @default.
• W2754031560 hasConceptScore W2754031560C2776670291 @default.
• W2754031560 hasConceptScore W2754031560C2776694085 @default.
• W2754031560 hasConceptScore W2754031560C2776755627 @default.
• W2754031560 hasConceptScore W2754031560C2777524225 @default.
• W2754031560 hasConceptScore W2754031560C2777543607 @default.
• W2754031560 hasConceptScore W2754031560C2777714996 @default.
• W2754031560 hasConceptScore W2754031560C2779075594 @default.
• W2754031560 hasConceptScore W2754031560C2779134260 @default.
• W2754031560 hasConceptScore W2754031560C2779338263 @default.
• W2754031560 hasConceptScore W2754031560C2780333948 @default.
• W2754031560 hasConceptScore W2754031560C2780653079 @default.
• W2754031560 hasConceptScore W2754031560C3018587741 @default.
• W2754031560 hasConceptScore W2754031560C55520419 @default.
• W2754031560 hasConceptScore W2754031560C71924100 @default.
• W2754031560 hasConceptScore W2754031560C75603125 @default.
• W2754031560 hasConceptScore W2754031560C90924648 @default.
• W2754031560 hasLocation W27540315601 @default.
• W2754031560 hasOpenAccess W2754031560 @default.
• W2754031560 hasPrimaryLocation W27540315601 @default.
• W2754031560 hasRelatedWork W1937058949 @default.
• W2754031560 hasRelatedWork W1991217264 @default.
• W2754031560 hasRelatedWork W2131069338 @default.
• W2754031560 hasRelatedWork W2213394156 @default.
• W2754031560 hasRelatedWork W2260881643 @default.
• W2754031560 hasRelatedWork W2322195208 @default.
• W2754031560 hasRelatedWork W2323350416 @default.
• W2754031560 hasRelatedWork W2336777967 @default.
• W2754031560 hasRelatedWork W2567205011 @default.
• W2754031560 hasRelatedWork W2580036316 @default.
• W2754031560 hasRelatedWork W2778567868 @default.
• W2754031560 hasRelatedWork W2781108436 @default.
• W2754031560 hasRelatedWork W2909262563 @default.
• W2754031560 hasRelatedWork W2909283919 @default.
• W2754031560 hasRelatedWork W2944065197 @default.
• W2754031560 hasRelatedWork W2982102520 @default.
• W2754031560 hasRelatedWork W2991273068 @default.
• W2754031560 hasRelatedWork W2992404880 @default.
• W2754031560 hasRelatedWork W3161987599 @default.
• W2754031560 hasRelatedWork W3176375612 @default.
• W2754031560 isParatext "false" @default.

• next